MX348814B - FORMULACION PARA ANTICUERPO ANTI-A4ß7. - Google Patents

FORMULACION PARA ANTICUERPO ANTI-A4ß7.

Info

Publication number
MX348814B
MX348814B MX2013012724A MX2013012724A MX348814B MX 348814 B MX348814 B MX 348814B MX 2013012724 A MX2013012724 A MX 2013012724A MX 2013012724 A MX2013012724 A MX 2013012724A MX 348814 B MX348814 B MX 348814B
Authority
MX
Mexico
Prior art keywords
antibody
formulations
formulation
vivo
exhibit
Prior art date
Application number
MX2013012724A
Other languages
English (en)
Spanish (es)
Other versions
MX2013012724A (es
Inventor
Palaniappan Vaithianathan
T Truong Nobel
M Varga Csanad
Diluzio Willow
Brown Jason
H Fox Irving
Scholz Catherine
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX348814(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MX2013012724A publication Critical patent/MX2013012724A/es
Publication of MX348814B publication Critical patent/MX348814B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Endocrinology (AREA)
MX2013012724A 2011-05-02 2012-05-02 FORMULACION PARA ANTICUERPO ANTI-A4ß7. MX348814B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161481533P 2011-05-02 2011-05-02
US201161550545P 2011-10-24 2011-10-24
US201261585859P 2012-01-12 2012-01-12
PCT/US2012/036072 WO2012151248A2 (en) 2011-05-02 2012-05-02 FORMULATION FOR ANTI-α4β7 ANTIBODY

Publications (2)

Publication Number Publication Date
MX2013012724A MX2013012724A (es) 2013-12-06
MX348814B true MX348814B (es) 2017-06-30

Family

ID=46085207

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2018003210A MX383317B (es) 2011-05-02 2012-05-02 FORMULACIÓN PARA ANTICUERPO ANTI-A4ß7.
MX2013012724A MX348814B (es) 2011-05-02 2012-05-02 FORMULACION PARA ANTICUERPO ANTI-A4ß7.
MX2016012776A MX356827B (es) 2011-05-02 2012-05-02 FORMULACION PARA ANTICUERPO ANTI-A4ß7.
MX2021006723A MX2021006723A (es) 2011-05-02 2013-10-31 Formulacion para anticuerpo anti-a4b7.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018003210A MX383317B (es) 2011-05-02 2012-05-02 FORMULACIÓN PARA ANTICUERPO ANTI-A4ß7.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2016012776A MX356827B (es) 2011-05-02 2012-05-02 FORMULACION PARA ANTICUERPO ANTI-A4ß7.
MX2021006723A MX2021006723A (es) 2011-05-02 2013-10-31 Formulacion para anticuerpo anti-a4b7.

Country Status (42)

Country Link
US (16) US20120282249A1 (enExample)
EP (4) EP3329965B1 (enExample)
JP (7) JP6190360B2 (enExample)
KR (8) KR101923378B1 (enExample)
CN (4) CN108129565B (enExample)
AR (1) AR086237A1 (enExample)
AU (7) AU2012250873B2 (enExample)
BR (1) BR112013028424A2 (enExample)
CA (2) CA2834867C (enExample)
CL (2) CL2013003146A1 (enExample)
CO (1) CO6801647A2 (enExample)
CR (1) CR20130677A (enExample)
CY (1) CY1119435T1 (enExample)
DK (2) DK2704798T3 (enExample)
DO (1) DOP2013000253A (enExample)
EA (1) EA032729B1 (enExample)
EC (2) ECSP13013050A (enExample)
ES (2) ES3016382T3 (enExample)
FI (1) FI3329965T3 (enExample)
GE (1) GEP201706734B (enExample)
HK (1) HK1249466A1 (enExample)
HR (2) HRP20171432T1 (enExample)
HU (2) HUE071510T2 (enExample)
IL (5) IL296838A (enExample)
LT (2) LT2704798T (enExample)
MA (1) MA35136B1 (enExample)
ME (1) ME02859B (enExample)
MX (4) MX383317B (enExample)
MY (2) MY172735A (enExample)
PE (2) PE20190405A1 (enExample)
PH (3) PH12013502236A1 (enExample)
PL (2) PL2704798T3 (enExample)
PT (2) PT3329965T (enExample)
RS (2) RS66809B1 (enExample)
SG (1) SG194652A1 (enExample)
SI (2) SI2704798T1 (enExample)
SM (2) SMT202500218T1 (enExample)
TW (3) TWI556828B (enExample)
UA (2) UA116189C2 (enExample)
UY (1) UY34053A (enExample)
WO (1) WO2012151248A2 (enExample)
ZA (3) ZA201308069B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2012151247A2 (en) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
TW201945032A (zh) * 2013-03-15 2019-12-01 德商艾伯維德國有限及兩合公司 抗-egfr抗體藥物結合物調配物
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015159254A1 (en) * 2014-04-16 2015-10-22 Biocon Ltd. Stable protein formulations comprising a molar excess of sorbitol
IL251136B (en) * 2014-10-06 2022-07-01 Chemocentryx Inc Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
WO2016105572A1 (en) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
CA2995046A1 (en) * 2015-08-11 2017-02-16 Osaka University Anti-human integrin beta-7 antibody
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
MX2018011169A (es) 2016-03-14 2018-12-06 Millennium Pharm Inc Metodo para prevenir la enfermedad del injerto contra huesped.
WO2017160700A1 (en) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
WO2017158393A1 (en) * 2016-03-18 2017-09-21 Oslo University Hospital Hf Methods of treating graft-versus-host disease
JP7069032B2 (ja) * 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
WO2017180594A1 (en) * 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
MA44864A (fr) 2016-05-04 2019-03-13 Icahn School Med Mount Sinai Trithérapie pour le traitement d'une maladie intestinale inflammatoire
JP7202893B2 (ja) * 2016-06-12 2023-01-12 武田薬品工業株式会社 炎症性腸疾患を治療する方法
KR20230164205A (ko) * 2016-10-07 2023-12-01 리제너론 파아마슈티컬스, 인크. 실온 안정성 동결건조된 단백질
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
SMT202200182T1 (it) * 2016-12-23 2022-05-12 Immunogen Inc Immunoconiugati diretti contro adam9 e metodi di utilizzo degli stessi
US20200179486A1 (en) * 2017-04-28 2020-06-11 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders
EP3624846B1 (en) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
US20200087401A1 (en) * 2017-05-26 2020-03-19 Millennium Pharmaceuticals, Inc. Methods for the treatment of chronic pouchitis
EP4360651A3 (en) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
KR20200069316A (ko) 2017-10-12 2020-06-16 노보 노르디스크 에이/에스 의료 요법에서의 세마글루타이드
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2019198101A1 (en) 2018-04-10 2019-10-17 Dr. Reddy’S Laboratories Limited Stable formulations of therapeutic antibody
AU2019253070A1 (en) 2018-04-10 2020-11-26 Dr. Reddy's Laboratories Limited Antibody formulation
SG11202009872YA (en) * 2018-04-10 2020-11-27 Dr Reddys Laboratories Ltd Stable antibody formulation
MX2020012939A (es) 2018-05-31 2021-02-15 Ono Pharmaceutical Co Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.
EP3810094A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20210363233A1 (en) 2018-06-20 2021-11-25 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN109239335A (zh) * 2018-09-11 2019-01-18 广州万孚生物技术股份有限公司 联检试纸条及其制备方法
WO2020123241A1 (en) * 2018-12-10 2020-06-18 Clear Creek Bio, Inc. Multiphasic dosing regimens for treating cancer
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
US20230096620A1 (en) * 2019-04-17 2023-03-30 Millennium Pharmaceuticals, Inc. Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
MA56130A (fr) * 2019-06-10 2022-04-13 Takeda Pharmaceuticals Co Procédés de culture cellulaire et compositions pour la production d'anticorps
TW202112800A (zh) * 2019-06-10 2021-04-01 美商千禧製藥公司 抗體純化方法及其組成物
CA3143167A1 (en) * 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Methods of producing an anti-.alpha.4.beta.7 antibody
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
CN113577281A (zh) * 2020-04-30 2021-11-02 中国科学院分子细胞科学卓越创新中心 调控整合素β亚基的试剂和方法
AR122983A1 (es) 2020-07-16 2022-10-19 Abbvie Inc ANTICUERPOS ANTI-a4b7
EP4281045A4 (en) * 2021-01-20 2024-12-18 Dr. Reddy's Laboratories Limited LYOPHILIZED ANTIBODY FORMULATIONS AND RELATED METHODS
BR112023022811A2 (pt) * 2021-05-07 2024-01-16 Dr Reddys Laboratories Ltd Formulações farmacêuticas de um anticorpo alfa-4-beta-7 de alta concentração e de vedolizumabe de alta concentração, e, métodos para controlar a formação de partículas subvisíveis em um anticorpo alfa-4-beta-7 e de variantes de carga ou agregados ou fragmentação do anticorpo em uma composição de anticorpo alfa-4-beta-7 de alta concentração, para controlar a opalescência em uma composição de anticorpo alfa-4-beta-7 de alta concentração e para preparar uma composição de anticorpo alfa-4-beta-7
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
WO2025133872A1 (en) * 2023-12-19 2025-06-26 Intas Pharmaceuticals Ltd. Method for reducing oxidation levels in vedolizumab during cell culture process
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
WO2025177214A1 (en) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Therapeutic methods

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US774216A (en) 1903-11-19 1904-11-08 Alexander F Ward Machine for pointing and lapping hoops.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE3852236T2 (de) 1987-08-11 1995-04-06 Univ Leland Stanford Junior Verfahren zur Kontrolle der Leukozyten-Extravasation.
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
WO1990007321A2 (en) 1988-12-23 1990-07-12 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte receptor homing sequences and their uses
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
IL113261A (en) 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2204890T3 (es) 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
DE69309906T2 (de) 1992-02-12 1997-11-06 Biogen, Inc., Cambridge, Mass. Behandlung für entzündungserkrankung des darmes
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1993023526A1 (en) 1992-05-21 1993-11-25 Center For Blood Research, Inc. A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON
AU5732694A (en) 1992-12-01 1994-06-22 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
WO1994013312A1 (en) 1992-12-15 1994-06-23 The Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
AU687790B2 (en) 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
NZ279730A (en) 1994-01-25 1998-04-27 Athena Neurosciences Inc Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
DE69637155T2 (de) 1995-02-10 2008-02-07 Millennium Pharmaceuticals, Inc., Cambridge Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
DE60235013D1 (de) 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
WO2003072040A2 (en) 2002-02-25 2003-09-04 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
WO2003099773A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
CN101077867B (zh) 2002-11-18 2012-10-10 坎莫森特里克斯公司 芳基磺酰胺
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
BRPI0403964B8 (pt) 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
ES2690079T3 (es) 2004-09-03 2018-11-19 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
WO2007061679A1 (en) 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
AU2007240507B2 (en) 2006-04-21 2013-07-18 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
JP5631591B2 (ja) 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
MX2009003982A (es) 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
KR20090104017A (ko) 2006-12-11 2009-10-05 에프. 호프만-라 로슈 아게 Ａ베타 항체 비경구 제제
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
MX2010001488A (es) * 2007-08-08 2010-03-01 Abbott Lab Composiciones y metodos para cristalizar anticuerpos.
WO2010100200A2 (en) 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
WO2010148337A1 (en) * 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
MY189494A (en) 2011-03-31 2022-02-16 Genentech Inc Methods of administering beta7 integrin antagonists
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2012151247A2 (en) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
US20170327584A1 (en) * 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
WO2016105572A1 (en) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
MA44864A (fr) 2016-05-04 2019-03-13 Icahn School Med Mount Sinai Trithérapie pour le traitement d'une maladie intestinale inflammatoire
JP7202893B2 (ja) * 2016-06-12 2023-01-12 武田薬品工業株式会社 炎症性腸疾患を治療する方法

Also Published As

Publication number Publication date
US20190076532A1 (en) 2019-03-14
EP2704798A2 (en) 2014-03-12
US10004808B2 (en) 2018-06-26
HK1249466A1 (en) 2018-11-02
HK1256106A1 (en) 2019-09-13
DK3329965T3 (da) 2025-04-07
AU2022231726A1 (en) 2022-10-06
KR101923378B1 (ko) 2018-11-29
KR20220154834A (ko) 2022-11-22
CN103608071B (zh) 2017-12-26
PE20190405A1 (es) 2019-03-14
JP2018150388A (ja) 2018-09-27
CR20130677A (es) 2014-10-07
US20200206353A1 (en) 2020-07-02
CN108129565B (zh) 2022-09-20
JP2019108400A (ja) 2019-07-04
ZA201308069B (en) 2016-01-27
PH12013502236A1 (en) 2014-01-06
US9663579B2 (en) 2017-05-30
KR102096484B1 (ko) 2020-04-02
AU2020250249A1 (en) 2020-11-05
WO2012151248A2 (en) 2012-11-08
ZA201707158B (en) 2019-01-30
EP2704798B1 (en) 2017-07-12
US12053526B2 (en) 2024-08-06
ECSP22034515A (es) 2022-05-31
LT2704798T (lt) 2017-10-25
PL3329965T3 (pl) 2025-04-28
JP6534415B2 (ja) 2019-06-26
TW201718012A (zh) 2017-06-01
US10143752B2 (en) 2018-12-04
HRP20250472T1 (hr) 2025-06-06
US20160340431A1 (en) 2016-11-24
ZA201806946B (en) 2022-03-30
KR20170116217A (ko) 2017-10-18
TW201247223A (en) 2012-12-01
EP3329965A1 (en) 2018-06-06
KR20200035503A (ko) 2020-04-03
JP6878489B2 (ja) 2021-05-26
MX2021006723A (es) 2022-05-03
TW201906631A (zh) 2019-02-16
KR20140145953A (ko) 2014-12-24
IL275038B (en) 2022-11-01
IL275038A (en) 2020-07-30
CO6801647A2 (es) 2013-11-29
US20190231878A1 (en) 2019-08-01
PT3329965T (pt) 2025-04-02
KR102275603B1 (ko) 2021-07-08
ES2645187T3 (es) 2017-12-04
DK2704798T3 (en) 2017-10-23
US20120282249A1 (en) 2012-11-08
TWI556828B (zh) 2016-11-11
AU2019201926A1 (en) 2019-04-11
CN108187042A (zh) 2018-06-22
MX2013012724A (es) 2013-12-06
CL2013003146A1 (es) 2014-07-25
JP6190360B2 (ja) 2017-08-30
US20250295786A1 (en) 2025-09-25
MY172735A (en) 2019-12-11
AR086237A1 (es) 2013-11-27
KR102465394B1 (ko) 2022-11-09
WO2012151248A3 (en) 2013-02-28
MA35136B1 (fr) 2014-05-02
SI2704798T1 (sl) 2017-12-29
HUE036663T2 (hu) 2018-07-30
US20140377251A1 (en) 2014-12-25
MY183471A (en) 2021-02-19
US20180207279A1 (en) 2018-07-26
SI3329965T1 (sl) 2025-07-31
EP3263178A1 (en) 2018-01-03
CA3028209A1 (en) 2012-11-08
CA2834867A1 (en) 2012-11-08
US20250000981A1 (en) 2025-01-02
KR20210084711A (ko) 2021-07-07
PH12018500030B1 (en) 2022-05-04
SG194652A1 (en) 2013-12-30
SMT202500218T1 (it) 2025-07-22
US20170002078A1 (en) 2017-01-05
PE20141175A1 (es) 2014-09-25
CN108129565A (zh) 2018-06-08
ECSP13013050A (es) 2014-01-31
CL2017000830A1 (es) 2017-12-22
CN108079291B (zh) 2022-04-08
JP2014514346A (ja) 2014-06-19
KR20180050435A (ko) 2018-05-14
JP7258941B2 (ja) 2023-04-17
RS56397B1 (sr) 2017-12-29
EP4378484A3 (en) 2024-09-04
UA126545C2 (uk) 2022-11-02
AU2025202434A1 (en) 2025-04-24
US12171832B2 (en) 2024-12-24
FI3329965T3 (fi) 2025-04-30
NZ617833A (en) 2016-04-29
TWI664978B (zh) 2019-07-11
AU2012250873A1 (en) 2013-05-09
GEP201706734B (en) 2017-09-25
ES3016382T3 (en) 2025-05-09
DOP2013000253A (es) 2013-12-31
PH12018500030A1 (en) 2018-10-15
JP2017137351A (ja) 2017-08-10
MX356827B (es) 2018-06-15
IL267668A (en) 2019-08-29
LT3329965T (lt) 2025-06-10
US20250288679A1 (en) 2025-09-18
JP7492057B2 (ja) 2024-05-28
JP2021113223A (ja) 2021-08-05
AU2018278866B2 (en) 2020-07-09
IL296847A (en) 2022-11-01
US20180289811A1 (en) 2018-10-11
US20160340432A1 (en) 2016-11-24
JP6473845B2 (ja) 2019-02-20
AU2016231469A1 (en) 2016-10-06
JP2023076616A (ja) 2023-06-01
IL267668B (en) 2020-10-29
US20250041424A1 (en) 2025-02-06
KR101923371B1 (ko) 2018-11-29
US20220370617A1 (en) 2022-11-24
EP3329965B1 (en) 2025-03-19
EP4378484A2 (en) 2024-06-05
IL296838A (en) 2022-11-01
EA201391614A1 (ru) 2014-07-30
BR112013028424A2 (pt) 2021-05-04
US9764033B2 (en) 2017-09-19
AU2020250249B2 (en) 2022-10-06
CN103608071A (zh) 2014-02-26
UA116189C2 (uk) 2018-02-26
US20210052733A1 (en) 2021-02-25
IL229104A0 (en) 2013-12-31
IL275038B2 (en) 2023-03-01
CA2834867C (en) 2019-02-12
EP3329965A3 (en) 2018-12-12
PL2704798T3 (pl) 2017-12-29
UY34053A (es) 2012-11-30
PT2704798T (pt) 2017-11-14
ME02859B (me) 2018-04-20
AU2022231726B2 (en) 2025-01-09
AU2012250873B2 (en) 2016-07-07
KR20250094743A (ko) 2025-06-25
PH12020500336A1 (en) 2021-02-22
JP2024098027A (ja) 2024-07-19
CA3028209C (en) 2021-01-05
AU2018278866A1 (en) 2019-01-03
RS66809B1 (sr) 2025-06-30
CY1119435T1 (el) 2018-03-07
TWI664980B (zh) 2019-07-11
SMT201700508T1 (it) 2017-11-15
HUE071510T2 (hu) 2025-09-28
EA032729B1 (ru) 2019-07-31
AU2016231469B2 (en) 2018-12-20
MX383317B (es) 2025-03-13
KR20180127540A (ko) 2018-11-28
CN108079291A (zh) 2018-05-29
HRP20171432T1 (hr) 2017-11-03

Similar Documents

Publication Publication Date Title
PH12020500336A1 (en) FORMULATION FOR ANTI-a4á7 ANTIBODY
PH12019501662A1 (en) FORMULATION FOR ANTI-a4á7 ANTIBODY
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
MY185139A (en) Substituted imidazopyridazines
MX348823B (es) Formulaciones estables de linaclotida.
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
TN2013000442A1 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
TN2013000455A1 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
UA112984C2 (uk) КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
IN2013MU02584A (enExample)

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration